Lifecore Biomedical Inc. (LFCR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Lifecore Biomedical Inc. (LFCR) is down 46.0% since the beginning of the year. At $4 per share, LFCR is trading 50.8% below its 52-week high of $9. Investors who bought $1,000 worth of LFCR shares 5 years ago would now be looking at an investment worth $404.

Lifecore Biomedical Inc. (LFCR) has returned -45.97% so far this year and -36.77% over the past 12 months. Over the last ten years, LFCR has returned -9.24% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.

Based on dividend-adjusted daily data since Feb 15, 1996, LFCR's average daily return is +0.07%, while the average monthly return is +0.77%. At this rate, an investment would double in approximately 7.5 years.

Historically, 49% of months were positive and 51% were negative. The best month was May 2023 with a return of +92.7%, while the worst month was Mar 2026 at -48.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.

On a daily basis, LFCR closed higher 45% of trading days. The best single day was Aug 24, 1999 with a return of +129.6%, while the worst single day was Mar 17, 2023 at -67.3%.

Lifecore Biomedical Inc. has an annualized alpha of 9.51%, beta of 0.80, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since February 15, 1996.

• This stock participated in 122.76% of S&P 500 Index downside but only 71.15% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LFCR ranks 18 for risk / return — above 18% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Lifecore Biomedical Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Lifecore Biomedical Inc. was 92.05%, occurring on Sep 20, 2002. The portfolio has not yet recovered.

The current Lifecore Biomedical Inc. drawdown is 78.70%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Lifecore Biomedical Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Lifecore Biomedical Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.